Arcutis Biotherapeutics, Inc. ARQT Customer receivables and Other

Customer receivables and Other at other companies

Morgan StanleyMS

$2.52B+0.4%

KEE

Keel Infrastructure Corp. Common StockKEEL

$134.75K+48.1%

Raymond James FinancialRJF

$1.81B-3.5%

Chicago Atlantic Real Estate FinanceREFI

$2.56M+388%

Arbor Realty TrustABR

$35.25M+267%

Ares Management CorporationARES

$0-100%

Segments

By segment

See full

Reportable Segment$2.28M-10.3%

Other financials

Income statement

See full

Revenue$105.4M+60.1%

Gross profit$95.6M+67.7%

Operating income-$9.1M+62.9%

Net income-$11.3M+54.9%

EPS (diluted)-$0.09+55.0%

Balance sheet

See full

Cash & equivalents$35.1M-34.7%

Total debt$114.7M+3.5%

Total equity$189.6M+32.9%

Total assets$460.0M+33.7%

Cash flow

See full

Operating cash flow$2.2M+107%

CapEx--100%

Free cash flow$2.2M+107%

Valuation

See full

Market cap$3.29B+57.5%

Profitability

See full

Gross margin90.9%+2.5pp

Operating margin-12%-5.7pp

Net margin-13.9%-6.6pp

FCF margin-52.5%-21.9pp

Returns & leverage

See full

Return on equity-28.2%-13.0pp

Debt / equity0.6×-0.2×

Current ratio2.7×-0.9×

Where this comes from

Reported directly by Arcutis Biotherapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:InterestIncomeOther.

The official record: Arcutis Biotherapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arcutis Biotherapeutics, Inc.'s customer receivables and other.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Arcutis Biotherapeutics, Inc.'s customer receivables and other?: Arcutis Biotherapeutics, Inc. (ARQT) reported customer receivables and other of $2.28M in Q1 2026.
How has Arcutis Biotherapeutics, Inc.'s customer receivables and other changed year-over-year?: Arcutis Biotherapeutics, Inc.'s customer receivables and other decreased by 10.3% year-over-year, from $2.54M to $2.28M.